FDAnews
www.fdanews.com/articles/209614-verismo-therapeutics-snags-orphan-drug-designation

Verismo Therapeutics Snags Orphan Drug Designation

September 30, 2022

The FDA has granted Verismo Therapeutics an Orphan Drug designation for its SynKIR-110 investigational treatment for patients with mesothelin-expressing mesotheliomas.

SynKIR-110 is a first-in-class cell therapy that uses killer immunoglobulin-like receptor (KIR) technology that enables T cells to switch on and off, allowing them to rest when not bound to the tumor.

Phase 1 clinical trials to evaluate the drug candidate in patients with mesothelin-expressing ovarian cancer, mesothelioma and cholangiocarcinoma will begin in the first quarter of 2023.

The FDA grants the Orphan Drug to drugs intended to treat a rare disease that affects fewer than 200,000 people in the United States and that show promise in the treatment, prevention or diagnosis of the disease.

View today's stories